Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 19, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 3,642,000 ordinary shares of 25 pence each.
- Repurchase Price: 1,113.88 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 8.93% of total voting rights).
- Shares in Issue: 5,308,311,839 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 3,642,000 shares on June 19, 2008. Consequently, the number of shares in issue was updated to 5,308,311,839. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,308,311,839) for accurate calculation of ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (8.93%).
- Note that this transaction involved the cancellation of shares, not their retention for future reissue.